Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AUMantagomir
- Development stage
- Preclinical
- Lead developer
- AUM BioTech
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Not Specified (preclinical Use Typically Involves Direct Application To Tissue Or Cell Culture)
01
Overview
AUMantagomir is a specialized antisense oligonucleotide designed for microRNA (miRNA) inhibition. It acts as an "antagomir," binding to specific miRNAs and preventing them from interacting with their natural mRNA targets, thereby blocking miRNA function and often leading to miRNA degradation. The technology is built on the AUM silence platform, which enables self-delivery—meaning these oligos can enter cells without transfection reagents and localize to both cytoplasm and nucleus. This feature makes them particularly useful for research in complex tissues such as neuronal cells. In preclinical studies, AUMantagomirs have demonstrated strong inhibition of miRNA activity and significant upregulation of target genes; for example, in rat hippocampal slices treated with an AUM antagomir against miR-134, there was a clear decrease in miR-134 levels and de-repression of its target genes[1].
- Brand names
- AUMantagomir
- Other names
- AUM antagomirsdASO™ (in context of self-delivering antisense oligonucleotide)AUM antagomir™
Beyond the preview
Go deeper on AUMantagomir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AUMantagomir.